Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multicenter open-label study of CPT in relapsed or refractory multiple myeloma
ChiCTR-ONC-12002065Phase 2Completed
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Sep 2007
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camptothecin in multiple myeloma (MM), sponsored by Beijing Chaoyang Hospital. Primary endpoints: Objective response rate and Adverse events. Started Sep 2007; status: completed.
02
Drugs
camptothecin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR-ONC-12002065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12002065.